Figure 2 suggests that the optimal treatment for glioma-bearing mice is an increased tumor site concentration of anti-PD-1 on days 12, 14, and 26 to 44, and the CCR2 antagonist from days 10 to 42, where both drugs are administered at a dose and frequency that allows them to obtain their maximum percent reductions during these periods. The gene discussed is CCR2; the disease is central nervous system cancer.